

Refine Search

Search Results -

Terms	Documents
\$carnitine adj15 liposome	15

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L8

Search History

DATE: Thursday, January 11, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L8</u>	\$carnitine adj15 liposome	15	<u>L8</u>
<u>L7</u>	L6 and 424/450.ccls.	13	<u>L7</u>
<u>L6</u>	\$carnitine same liposome	430	<u>L6</u>
<u>L5</u>	L4 and liposome	2	<u>L5</u>
<u>L4</u>	acetyl\$carnitine and 424/450.ccls.	4	<u>L4</u>
<u>L3</u>	acetyl\$carnitine	561	<u>L3</u>
<u>L2</u>	alkyl\$carnitine	0	<u>L2</u>
<u>L1</u>	alkyl\$carnitine and 424/450.ccls.	0	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)**End of Result Set**

Generate Collection

Print

L5: Entry 2 of 2

File: USPT

Dec 25, 2001

DOCUMENT-IDENTIFIER: US 6333057 B1

TITLE: Composition and method for topical treatment of androgenic alopecia

Brief Summary Text (25):

The term "acetyl carnitine" refers to various forms of acetyl carnitine, including but not limited to, D,L-carnitine, and acetyl-L-carnitine hydrochloride which is usually employed in a 1% to 5% solution. Acetyl carnitine (PCAA, Houston, Tex.) is thought to decrease in senescence and down regulation. Although not wanting to be bound by this statement, it is believed that the decrease in acetyl carnitine compromises the transport of fatty acids from the cytosol into the inner mitochondrial membrane of the mitochondria, thereby impairing the physiological function of the follicle, perhaps through effects on fatty acid oxidation and ATP production. Acetyl carnitine is believed to improve fatty acid metabolism by stimulation of cardiolipin which affects the activity of the inner mitochondrial membrane, affecting its permeability and function for proton transport. Acetyl carnitine is also believed to synergize with co-enzyme Q in the revitalization of senescent hair follicles.

Brief Summary Text (29):

"Topical" application is used to mean local administration of the composition and its various embodiments, for example, in the treatment of alopecia. The composition according to the present invention can be in the form of solutions, lotions, salves, creams, ointments, liposomes, sprays, gels, roller sticks or any other method using micelles and pharmaceutically acceptable penetration enhancers. In one embodiment, the composition may be applied to the scalp at bedtime and again after showering in the morning for a total of two applications per day.

Brief Summary Text (36):

The present invention optionally includes lecithin (20% -98%) dissolved with isopropyl palmitate or other solvents in combination with an approximately 10% -20% solution of PLURONIC F-127 (BASF, Parsippany, N.J.), otherwise known as poloxamer 407, in a ratio of approximately 1:3 to 1:4. This ratio may be varied by one of ordinary skill in the art. Other PLURONICS may be used in the present invention. It is to be understood that the soy lecithin of the present invention is a preferred lecithin source and may be dissolved in isopropyl palmitate to achieve a final concentration in the composition of from approximately 20% -98%, with a more preferred final concentration of from approximately 20%-40%. Lecithins may optionally be derived from eggs, and organs such as heart, brain, and liver, and used at concentrations of approximately 20%-99%, with more preferred final concentrations of from approximately 20%-40%. The composition according to the present invention can be in the form of lotions, salves, creams, ointments, liposomes, sprays, micelles, or gels. The desired form is lotions, ointments and salves. Liposomes are described in detail by Oleniacz in U.S. Pat. No. 3,957,971, the entirety of which is hereby incorporated by reference.

Current US Cross Reference Classification (1):

424/450

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L7: Entry 4 of 13

File: PGPB

Apr 4, 2002

DOCUMENT-IDENTIFIER: US 20020039595 A1

TITLE: ORAL LIPOSOMAL DELIVERY SYSTEM

Current US Classification, US Primary Class/Subclass:

424/450

Detail Description Paragraph:

[0028] Components are commingled and liposomes are made using the injection method (Lasic, D., Liposomes, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting one gram capsule contains 735 mg of L-Carnitine. Filling of gel caps on a large scale is best with the rotary die method or others such as the Norton capsule machine.

CLAIMS:

8. The liposome-capsule dosage unit of claim 1 wherein the biologically active material is L-Carnitine.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L7: Entry 7 of 13

File: USPT

Apr 27, 2004

DOCUMENT-IDENTIFIER: US 6726924 B2

TITLE: Oral liposomal delivery system

Detailed Description Text (9):

Components are commingled and liposomes are made using the injection method (Lasic, D., Liposomes, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting one gram capsule contains 735 mg of L-Carnitine. Filling of gel caps on a large scale is best with the rotary die method or others such as the Norton capsule machine.

Current US Original Classification (1):424/450[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)

L8: Entry 12 of 15

File: DWPI

Nov 1, 2001

DERWENT-ACC-NO: 2002-264987

DERWENT-WEEK: 200231

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Cosmetic composition for improving skin

INVENTOR: CHO, B G; KIM, B J ; LEE, S J

PATENT-ASSIGNEE: COREANA COSMETICS CO LTD (COREN)

PRIORITY-DATA: 2000KR-0016922 (March 31, 2000)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> KR 2001094548 A	November 1, 2001		000	A61K007/00

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
KR2001094548A	March 31, 2000	2000KR-0016922	

INT-CL (IPC): A61K 7/00

ABSTRACTED-PUB-NO: KR2001094548A

BASIC-ABSTRACT:

NOVELTY - Provided is a cosmetic composition containing esculin, L-carnitine, caffeine, and ruscogenin to improve sagging face, waist and breast, skin texture and obesity caused by lipid accumulation.

DETAILED DESCRIPTION - The cosmetic composition contains 0.05-20.0, preferably 0.1-10 wt.% of slimming liposome based on the total weight of cosmetic composition. The slimming liposome includes 0.001-30., preferably 0.01-1.0 wt.% of esculin, 0.001-3.0, preferably 0.01-1.0 wt.% of L-carnitine, 0.001-3.0, preferably 0.0-1.0 wt.% of caffeine and 0.001-5.0, preferably 0.05-2.0 wt.% of ruscogenin which are stabilized by liposome technique. The slimming liposome is pseudo liposome having a particle size less than 300 nm and manufactured by using phospholipid and carrier oil, such as collagen and GAGs.

ABSTRACTED-PUB-NO: KR2001094548A

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: D21 E19

CPI-CODES: D08-B09A; E01; E06-A01; E06-D09; E10-A22D;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20030068365 A1

L5: Entry 1 of 2

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068365

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030068365 A1

TITLE: Compositions and methods for administration of active agents using liposome beads

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Suvanprakorn, Pichit	Bangkok	FL	TH
Ploysangam, Tanusin	Bangkok		TH
Tanasugarn, Lerson	Bangkok		TH
Chandrkrachang, Suwalee	Bangkok		TH
Zaias, Nardo	Miami Beach		US

US-CL-CURRENT: 424/450; 424/725

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 6333057 B1

L5: Entry 2 of 2

File: USPT

Dec 25, 2001

US-PAT-NO: 6333057

DOCUMENT-IDENTIFIER: US 6333057 B1

TITLE: Composition and method for topical treatment of androgenic alopecia

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crandall; Wilson T.	Ft. Defiance	VA	24437	

US-CL-CURRENT: 424/727; 424/450, 424/484, 424/489, 424/70.1, 514/170, 514/690, 514/78, 514/880, 514/930, 514/944, 514/946, 514/951, 514/959, 514/961

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L4 and liposome	2

Display Format: [Change Format](#)

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
\$carnitine adj5 vascular	36

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L4



Search History

DATE: Thursday, January 11, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name **Query**
 side by side

Hit Count **Set Name**
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L4</u>	\$carnitine adj5 vascular	36	<u>L4</u>
<u>L3</u>	L2 and liposome	72	<u>L3</u>
<u>L2</u>	\$carnitine same vascular	220	<u>L2</u>
<u>L1</u>	\$carnitine same liposome same vascular	0	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 10 of 36

File: USPT

Nov 4, 2003

DOCUMENT-IDENTIFIER: US 6641849 B1

TITLE: Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of L-carnitine and extracts of ginkgo biloba

Brief Summary Text (37):

A series of tests was conducted using the method described by Young (Young J. N., Prostaglandins 30:545, 1985) and by Myers (Myers H., Br. J. Pharmacol., 79:595, 1983) in order to assess whether Ginkgo biloba extracts (whose anti-PAF activity is known) protect animals injected with PAF against death and whether the carnitines (particularly propionyl L-carnitine, whose vascular regulatory activity is known) are capable of increasing the protective effect against PAF.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 11 of 36

File: USPT

Jun 3, 2003

DOCUMENT-IDENTIFIER: US 6573299 B1

TITLE: Method and compositions for treatment of the aging eye

Brief Summary Text (47):

The use of NOS inhibitors is well known in the art. Cavazza, U.S. Pat. Nos. 5,432,199 and 5,747,536, discloses the use of L-carnitine and resveratrol to treat peripheral vascular diseases and peripheral diabetic neuropathy or acetyl D-carnitine to treat glaucoma. Dawson et al, U.S. Pat. No. 5,266,594, discloses a method of preventing or treating glutamate neurotoxicity with a NOS inhibitor capable of penetrating the blood brain barrier. Ahluwalia et al, U.S. Pat. No. 5,468,476, discloses a method of reducing hair growth with a NOS inhibitor. Wahl et al, U.S. Pat. No. 5,449,688, discloses a method for treating chronic inflammatory conditions by parenterally or intravenously administering a NOS inhibitor. Stamler et al, U.S. Pat. No. 5,545,614, discloses a method for stimulating skeletal muscle contractions with a NOS inhibitor. Moncada et al, U.S. Pat. No. 5,585,402, discloses a method for inhibiting tissue damage by using a NOS inhibitor to decrease NO production in vascular endothelial cells. Dunn et al, U.S. Pat. No. 5,665,757, discloses a method for treating anxiety using a NOS inhibitor. Mjalli et al, U.S. Pat. No. 5,723,451, discloses a method for inhibiting NOS using one of eleven formulations. None of the above cited patents teach or suggest the use of the composition and method outlined in the present invention.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 26 of 36

File: USPT

Nov 6, 1990

DOCUMENT-IDENTIFIER: US 4968719 A

TITLE: Method for treating vascular disease

Abstract Text (1):

L-carnitine is effective for the treatment of peripheral vascular diseases, such as intermittent claudication. Administration of L-carnitine to patients suffering from intermittent claudication results in a significant increase in the distance the patients can walk before experiencing claudication.

Detailed Description Text (33):

Table 5 shows changes in total, free, and esterified carnitine concentrations induced by L-carnitine in patients with peripheral vascular disease. Normal values were obtained from six normal subjects matched to the patients with peripheral arterial disease with respect to age and sex, chosen from a group of 46 normal individual previously studied.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)[Generate Collection](#)[Print](#)

L4: Entry 31 of 36

File: USPT

Aug 10, 1982

DOCUMENT-IDENTIFIER: US 4343816 A

TITLE: Pharmaceutical composition comprising an acyl-carnitine, for treating peripheral vascular diseases[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)